摘要
目的探讨血清胃蛋白酶原(PGⅠ)、胃泌素-17(G-17)水平在胃癌筛查中的临床意义。方法于2021年10月~2022年2月在本院因消化道症状就诊的241患者。所有研究对象进行胃镜检查,根据胃镜检查结果,把研究对象分为慢性非萎缩性组、慢性萎缩组、早期胃癌组、进展期胃癌组四组,比较各组间血清PGⅠ、PGⅡ水平及PGR以及G17、HP抗体差异。结果早期胃癌组PG I、PG II、G-17较慢性非萎缩胃炎组、慢性萎缩性胃炎组、进展期胃癌组有升高(P<0.05);H.pylori抗体在慢性非萎缩性胃炎、慢性萎缩性胃炎、早期胃癌、进展期胃癌的病程进展阳性率相比有升高趋势,但差异无统计学意义(P>0.05);与慢性非萎缩性胃炎相比,进展期胃癌PGR水平有降低趋势,差异无统计学意义(P>0.05)。结论H.pylori抗体阳性率在早期胃癌诊断中有价值;PGI、PGII及G-17对萎缩性胃炎及早期胃癌的诊断有价值,其中PGII对早期胃癌有更好的诊断价值。
Objective:To investigate the clinical significance of serum pepsinogen(PGⅠ)and gastrin-17(G-17)levels in gastric cancer screening.Methods:From October 2020 to February 2021,a total of 241 patients visiting our hospital due to gastrointestinal symptoms received gastroscopy,and according to the results of gastroscopy,the study subjects were divided into four groups:chronic non-atrophic gastritis group,chronic atrophic gastritis group,early gastric cancer group and advanced gastric cancer group,and the dif⁃ferences in serum PG I and PG II levels and PGR,as well as G17 and HP antibodies were compared between the groups.Result:PG I,PG II and G-17 were elevated in the early gastric cancer group compared with those in the chronic non-atrophic gastritis group,chron⁃ic atrophic gastritis group and advanced gastric cancer group,and the difference was statistically significant(P<0.05);the positive rate of H.pylori antibody in the course of disease progression in the chronic non-atrophic gastritis,chronic atrophic gastritis,early gastric cancer,and advanced gastric cancer compared with the trend of elevation,but the difference was not statistically significant(P>0.05).Compared with chronic non-atrophic gastritis,there was a tendency for the PGR level of advanced gastric cancer to decrease,but the difference was not statistically significant(P>0.05).Conclusion:The positive rate of H.pylori antibody is valuable in the diag⁃nosis of early gastric cancer;PGI,PGII,and G-17 are valuable in the diagnosis of atrophic gastritis and early gastric can⁃cer,among which PGII has better diagnostic value for early gastric cancer.
作者
次仁央金
杨瑞芳
格桑央金
扎西曲珍
戴芸
Tsering Yangjin;Yang Ruifang;Kelsang Yangjin;Tashi Quzhen;Dai Yun(Tibet Autonomous Region People's Hospital,Lhasa,Tibet 850000,China;School of Medicine,Tibet University,Lhasa,Tibet 850000,China;Peking University First Hospital,Beijing 100000,China)
出处
《西藏医药》
2024年第1期104-106,共3页
Tibetan Medicine
